In short
Fidanacogene Elaparvovec is an innovative gene therapy being studied in clinical trials for the treatment of moderate to severe hemophilia B. This therapy aims to provide a long-lasting solution for patients by introducing a modified gene that helps produce the clotting factor IX, which is deficient in people with hemophilia B. The ongoing clinical trials are evaluating the safety and effectiveness of this potential breakthrough treatment.
At a glance
- Study Type
- Phase 3, open-label, single-arm study
- Participants
- Adult males (18-65 years) with moderate to severe hemophilia B (FIX:C ≤2%)
- Intervention
- Single infusion of Fidanacogene Elaparvovec (PF-06838435)
- Primary Endpoint
- Non-inferiority on annualized bleeding rate (ABR) from Week 12 to Month 15 compared to usual care
- Secondary Endpoints
- Factor IX activity levels, annualized infusion rate, quality of life measures, safety assessments
- Follow-up Duration
- Up to 6 years post-infusion
- Key Exclusion Criteria
- History of FIX inhibitors, significant liver disease, active hepatitis B or C, planned surgeries
What is Fidanacogene Elaparvovec?
Fidanacogene elaparvovec, also known by its product code PF-06838435, is an innovative gene therapy being developed to treat moderate to severe hemophilia B. This therapy is classified as an advanced therapy medicinal product, specifically a gene transfer product.
How Does It Work?
Fidanacogene elaparvovec uses a specially designed virus (called a viral vector) to deliver a functional copy of the Factor IX (FIX) gene to patients' cells. This gene has been modified to produce a highly active variant of FIX known as Padua. The therapy is administered as a single intravenous infusion, with the goal of providing long-term production of the FIX protein in the patient's body.
Target Condition: Hemophilia B
Hemophilia B is a rare genetic bleeding disorder caused by a deficiency in Factor IX, a crucial protein for blood clotting. Patients with moderate to severe hemophilia B (defined as having 2% or less of normal FIX activity) experience frequent spontaneous bleeding episodes, which can lead to joint damage and other serious complications.
Clinical Trial Details
A Phase 3 clinical trial, known as BENEGENE-2, is currently evaluating the efficacy and safety of fidanacogene elaparvovec. Key aspects of the trial include:
- It's an open-label, single-arm study, meaning all participants receive the therapy.
- The main goal is to demonstrate the effectiveness of a single infusion in adult males with moderate to severe hemophilia B.
- The study will last for 6 years after the infusion to assess long-term effects and durability of the treatment.
Eligibility Criteria
The trial has specific criteria for participants, including:
- Male patients aged 18-65 years
- Diagnosed with moderate to severe hemophilia B (FIX activity ≤2%)
- Previous experience with FIX therapy (at least 50 exposure days)
- No history of FIX inhibitors
- Acceptable liver function and no significant liver disease
Potential Benefits
The potential benefits being investigated include:
- Reduced bleeding episodes
- Decreased need for regular FIX replacement therapy
- Improved quality of life
- Better joint health
- Long-lasting effects from a single treatment
Safety Considerations
As with any new therapy, safety is a crucial aspect being monitored in the trial. Some key safety considerations include:
- Potential immune responses to the therapy
- Liver function changes
- Risk of developing inhibitors to FIX
- Possibility of thrombotic events (blood clots)
Future Prospects
If successful, fidanacogene elaparvovec could represent a significant advancement in the treatment of hemophilia B. It has the potential to provide long-term relief from symptoms with a single treatment, potentially transforming the lives of patients who currently require regular infusions of FIX.
As the clinical trial progresses, more information will become available about the effectiveness and safety of this promising gene therapy. Patients with hemophilia B and their healthcare providers should stay informed about the latest developments in this field.